Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence

被引:0
|
作者
Eva Esteban Cardeñosa
Pascual Bolufer Gilabert
Inmaculada de Juan Jiménez
Sarai Palanca Suela
Eva Barragán González
Virginia González Anguix
Enrique Lerma Alejos
Isabel Chirivella González
Ángel Segura Huerta
Carmen Guillén Ponce
Eduardo Martínez de Dueñas
Dolores Cuevas Cuerda
Dolores Salas Trejo
机构
[1] University Hospital La Fe,Laboratory of Molecular Biology. Service of Clinical Analysis
[2] Hospital Clínico Universitario,Unit of Genetic Counselling in Cancer
[3] Hospital Universitario La Fe,Unit of Genetic Counselling in Cancer
[4] Hospital General de Elche,Unit of Genetic Counselling in Cancer
[5] Consorcio Hospital Provincial,Unit of Genetic Counselling in Cancer
[6] Health Agency of Valencia,Service of Protocolization and Assistance Integration, Healthcare General Directorate
[7] Consellería de Sanitat,Cancer Plan Office, Department of Public Health
来源
Familial Cancer | 2010年 / 9卷
关键词
Breast cancer; Ovarian cancer; /; mutations; Family selection criteria; Tumor incidence;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study is to analyze the relationship of the incidence of mutations in the two major genes BRCA1 and BRCA2 conferring risk of breast cancer (BC) and ovarian cancer (OC) with the cancer burden in families and with the presence and age of onset of BC/OC. We included 704 index patients (IP) and 668 family members of the IP who tested positive for BRCA1/BRCA2 who were studied in the Program of Genetic Counselling in Cancer of the Valencia Community (Spain). We found 129 IPs with deleterious mutations (18.3%), 59 in BRCA1 and 70 in BRCA2, detecting 396 mutations in this kindred. The incidence of mutations and their distribution between BRCA1 and BRCA2 showed a significantly uneven incidence among the family groups (P < 0.001). We found 179 tumors in the 396 mutation carriers (45%) and detected only 11 cancers among the 272 non-mutation carriers (P < 0.001). No differences in the tumor prevalence or the age of onset of cancer between the genes among the mutation carriers were found. The mutation carriers showed a 50% probability of having BC/OC at a median age of 49 years (95% CI 46–52 years) and 78% at the age of 70 years (95% CI: 71–85%). In conclusion the family burden of BC and OC is strongly associated with the incidence of BRCAs mutations and could foretell which of the two BRCAs genes is more likely to have mutations. Mutation carriers have a 50% risk of having BC/OC by the age of 50 years.
引用
收藏
页码:291 / 295
页数:4
相关论文
共 50 条
  • [21] PREVALENCE AND INCIDENCE OF PANCREAS PATHOLOGY IN PATIENTS WITH BRCA1 AND BRCA2 MUTATIONS
    Shah, Ishani
    Mlabasati, Jack
    Kandasamy, Cinthana
    Huang, Dora C.
    Wadhwa, Vaibhav
    Bilal, Mohammad
    Germansky, Katharine A.
    Cohen, Jonah
    Berzin, Tyler M.
    Pleskow, Douglas K.
    Sawhney, Mandeep
    GASTROINTESTINAL ENDOSCOPY, 2021, 93 (06) : AB245 - AB245
  • [22] Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations
    Roukos, Dimitrios H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15): : 1555 - 1556
  • [23] BRCA1 and BRCA2 mutations in patients with familial breast cancer
    Bolufer, P
    Munárriz, B
    Santaballa, A
    Velasco, E
    Lerma, E
    Barragán, E
    MEDICINA CLINICA, 2005, 124 (01): : 10 - 12
  • [24] BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer
    Niell, BL
    Rennert, G
    Bonner, JD
    Almog, R
    Tomsho, LP
    Gruber, SB
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01): : 15 - 21
  • [25] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
    Ganguly, Shuvadeep
    Gogia, Ajay
    LANCET ONCOLOGY, 2022, 23 (07): : E314 - E314
  • [26] Breast cancer survival in carriers of BRCA1 and BRCA2 mutations
    Rennert, G.
    Bisland, S.
    Bar Joseph, N.
    Zhang, S.
    Rennert, H. S.
    Barnett-Griness, O.
    Narod, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia
    Wafa Troudi
    N. Uhrhammer
    C. Sibille
    C. Dahan
    W. Mahfoudh
    C. Bouchlaka Souissi
    T. Jalabert
    L. Chouchane
    Y. J. Bignon
    F. Ben Ayed
    A. Ben Ammar Elgaaied
    Journal of Human Genetics, 2007, 52 : 915 - 920
  • [28] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [29] BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer
    Friedenson, B
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1184 - 1185
  • [30] Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Hyman, David M.
    Spriggs, David R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 408 - 410